CN113995826A - External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof - Google Patents
External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof Download PDFInfo
- Publication number
- CN113995826A CN113995826A CN202111388635.XA CN202111388635A CN113995826A CN 113995826 A CN113995826 A CN 113995826A CN 202111388635 A CN202111388635 A CN 202111388635A CN 113995826 A CN113995826 A CN 113995826A
- Authority
- CN
- China
- Prior art keywords
- juice
- tail wine
- traditional chinese
- infusion
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001802 infusion Methods 0.000 title claims abstract description 52
- 208000010195 Onychomycosis Diseases 0.000 title claims abstract description 44
- 201000005882 tinea unguium Diseases 0.000 title claims abstract description 44
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 99
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 53
- 235000008397 ginger Nutrition 0.000 claims abstract description 53
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 claims abstract description 29
- 240000008384 Capsicum annuum var. annuum Species 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 23
- 238000001914 filtration Methods 0.000 claims abstract description 20
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 16
- 238000002791 soaking Methods 0.000 claims description 16
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 240000007594 Oryza sativa Species 0.000 claims description 10
- 235000007164 Oryza sativa Nutrition 0.000 claims description 10
- 235000009566 rice Nutrition 0.000 claims description 9
- 240000006394 Sorghum bicolor Species 0.000 claims description 7
- 235000011684 Sorghum saccharatum Nutrition 0.000 claims description 7
- 235000013339 cereals Nutrition 0.000 claims description 7
- 238000003892 spreading Methods 0.000 claims description 6
- 230000007480 spreading Effects 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000010025 steaming Methods 0.000 claims description 5
- 238000010411 cooking Methods 0.000 claims description 2
- 238000007789 sealing Methods 0.000 claims description 2
- 244000273928 Zingiber officinale Species 0.000 claims 5
- 244000089698 Zanthoxylum simulans Species 0.000 claims 1
- 241000234314 Zingiber Species 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 14
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 7
- 230000001954 sterilising effect Effects 0.000 abstract description 7
- 238000002386 leaching Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 210000000282 nail Anatomy 0.000 description 18
- 229940079593 drug Drugs 0.000 description 16
- 230000002401 inhibitory effect Effects 0.000 description 14
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 12
- 241000222122 Candida albicans Species 0.000 description 11
- 229940095731 candida albicans Drugs 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 241000191967 Staphylococcus aureus Species 0.000 description 10
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 10
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 10
- 235000002780 gingerol Nutrition 0.000 description 10
- OJYLAHXKWMRDGS-UHFFFAOYSA-N zingerone Chemical compound COC1=CC(CCC(C)=O)=CC=C1O OJYLAHXKWMRDGS-UHFFFAOYSA-N 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 241000949456 Zanthoxylum Species 0.000 description 8
- 229940087305 limonene Drugs 0.000 description 7
- 235000001510 limonene Nutrition 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 235000007650 Aralia spinosa Nutrition 0.000 description 6
- 239000004744 fabric Substances 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 5
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000588769 Proteus <enterobacteria> Species 0.000 description 4
- 241000607764 Shigella dysenteriae Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- -1 ciclopirox olamine ketone Chemical class 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 229960004130 itraconazole Drugs 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 4
- 229960002722 terbinafine Drugs 0.000 description 4
- 241001480043 Arthrodermataceae Species 0.000 description 3
- 241000228245 Aspergillus niger Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 230000037304 dermatophytes Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 229960004884 fluconazole Drugs 0.000 description 3
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 229940007046 shigella dysenteriae Drugs 0.000 description 3
- FAMPSKZZVDUYOS-UHFFFAOYSA-N 2,6,6,9-tetramethylcycloundeca-1,4,8-triene Chemical compound CC1=CCC(C)(C)C=CCC(C)=CCC1 FAMPSKZZVDUYOS-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229940040145 liniment Drugs 0.000 description 2
- 239000000865 liniment Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- IGGUPRCHHJZPBS-UHFFFAOYSA-N nonacosane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCC IGGUPRCHHJZPBS-UHFFFAOYSA-N 0.000 description 2
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 2
- 229960001180 norfloxacin Drugs 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- XNGKCOFXDHYSGR-UHFFFAOYSA-N perillene Chemical compound CC(C)=CCCC=1C=COC=1 XNGKCOFXDHYSGR-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- YHQGMYUVUMAZJR-UHFFFAOYSA-N α-terpinene Chemical compound CC(C)C1=CC=C(C)CC1 YHQGMYUVUMAZJR-UHFFFAOYSA-N 0.000 description 2
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 2
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- LFJQCDVYDGGFCH-JTQLQIEISA-N (+)-β-phellandrene Chemical compound CC(C)[C@@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-JTQLQIEISA-N 0.000 description 1
- WTARULDDTDQWMU-RKDXNWHRSA-N (+)-β-pinene Chemical compound C1[C@H]2C(C)(C)[C@@H]1CCC2=C WTARULDDTDQWMU-RKDXNWHRSA-N 0.000 description 1
- LFJQCDVYDGGFCH-SNVBAGLBSA-N (+/-)-beta-Phellandrene Natural products CC(C)[C@H]1CCC(=C)C=C1 LFJQCDVYDGGFCH-SNVBAGLBSA-N 0.000 description 1
- WTARULDDTDQWMU-IUCAKERBSA-N (-)-Nopinene Natural products C1[C@@H]2C(C)(C)[C@H]1CCC2=C WTARULDDTDQWMU-IUCAKERBSA-N 0.000 description 1
- GRWFGVWFFZKLTI-IUCAKERBSA-N (-)-α-pinene Chemical compound CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 1
- MQHLMHIZUIDKOO-OKZBNKHCSA-N (2R,6S)-2,6-dimethyl-4-[(2S)-2-methyl-3-[4-(2-methylbutan-2-yl)phenyl]propyl]morpholine Chemical compound C1=CC(C(C)(C)CC)=CC=C1C[C@H](C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-OKZBNKHCSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001716 (4-methyl-1-propan-2-yl-1-cyclohex-2-enyl) acetate Substances 0.000 description 1
- FQTLCLSUCSAZDY-KAMYIIQDSA-N (6Z)-nerolidol Chemical compound CC(C)=CCC\C(C)=C/CCC(C)(O)C=C FQTLCLSUCSAZDY-KAMYIIQDSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- JJWDELPVPRCLQN-UHFFFAOYSA-N 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;hydrochloride Chemical compound Cl.C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 JJWDELPVPRCLQN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- WSTYNZDAOAEEKG-UHFFFAOYSA-N Mayol Natural products CC1=C(O)C(=O)C=C2C(CCC3(C4CC(C(CC4(CCC33C)C)=O)C)C)(C)C3=CC=C21 WSTYNZDAOAEEKG-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- TWGHMXOYRUTQOL-UHFFFAOYSA-N O-Methylconfusameline Natural products COC1=C2C=COC2=NC2=CC(OC)=CC=C21 TWGHMXOYRUTQOL-UHFFFAOYSA-N 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 241000722363 Piper Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N Pseudopinene Natural products C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- HCUSLQJBGQJQCB-UHFFFAOYSA-N Schinifoline Chemical compound C1=CC=C2N(C)C(CCCCCCC)=CC(=O)C2=C1 HCUSLQJBGQJQCB-UHFFFAOYSA-N 0.000 description 1
- SLSIBLKBHNKZTB-UHFFFAOYSA-N Skimmianine Chemical compound COC1=C2C=COC2=NC2=C(OC)C(OC)=CC=C21 SLSIBLKBHNKZTB-UHFFFAOYSA-N 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- XCPQUQHBVVXMRQ-UHFFFAOYSA-N alpha-Fenchene Natural products C1CC2C(=C)CC1C2(C)C XCPQUQHBVVXMRQ-UHFFFAOYSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- IGODOXYLBBXFDW-UHFFFAOYSA-N alpha-Terpinyl acetate Chemical compound CC(=O)OC(C)(C)C1CCC(C)=CC1 IGODOXYLBBXFDW-UHFFFAOYSA-N 0.000 description 1
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 229960003204 amorolfine Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 1
- LFJQCDVYDGGFCH-UHFFFAOYSA-N beta-phellandrene Natural products CC(C)C1CCC(=C)C=C1 LFJQCDVYDGGFCH-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960004375 ciclopirox olamine Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- LCWMKIHBLJLORW-UHFFFAOYSA-N gamma-carene Natural products C1CC(=C)CC2C(C)(C)C21 LCWMKIHBLJLORW-UHFFFAOYSA-N 0.000 description 1
- BXWQUXUDAGDUOS-UHFFFAOYSA-N gamma-humulene Natural products CC1=CCCC(C)(C)C=CC(=C)CCC1 BXWQUXUDAGDUOS-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- HIGQPQRQIQDZMP-UHFFFAOYSA-N geranil acetate Natural products CC(C)=CCCC(C)=CCOC(C)=O HIGQPQRQIQDZMP-UHFFFAOYSA-N 0.000 description 1
- HIGQPQRQIQDZMP-DHZHZOJOSA-N geranyl acetate Chemical compound CC(C)=CCC\C(C)=C\COC(C)=O HIGQPQRQIQDZMP-DHZHZOJOSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- QBNFBHXQESNSNP-UHFFFAOYSA-N humulene Natural products CC1=CC=CC(C)(C)CC=C(/C)CCC1 QBNFBHXQESNSNP-UHFFFAOYSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- DOMJKIVDRZSIJN-UHFFFAOYSA-N kokusaginine Natural products COC12Cc3ncccc3CC1(OC)C=CO2 DOMJKIVDRZSIJN-UHFFFAOYSA-N 0.000 description 1
- 125000000396 limonene group Chemical group 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- HIGQPQRQIQDZMP-FLIBITNWSA-N neryl acetate Chemical compound CC(C)=CCC\C(C)=C/COC(C)=O HIGQPQRQIQDZMP-FLIBITNWSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WUXSWGVAYSJTJS-UHFFFAOYSA-N pentacyclo[4.2.0.02,5.03,8.04,7]oct-1-ene Chemical compound C12C3C4=C1C1C2C3C14 WUXSWGVAYSJTJS-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- SACPYSHBQFRBLR-UHFFFAOYSA-N skimmianine Natural products COC1=C2C=COC2Nc3c(OC)c(OC)ccc13 SACPYSHBQFRBLR-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 229940126703 systemic medication Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, and in particular relates to an external infusion for treating onychomycosis by a traditional Chinese medicine composition and a preparation method thereof, wherein the external infusion comprises the following components in parts by weight: 40-50 parts of tail wine, 2-10 parts of ginger juice and 2-5 parts of green pepper juice. The preparation method comprises the following steps: mixing the tail wine, rhizoma Zingiberis recens juice and green fructus Zanthoxyli juice at a certain proportion, standing for 18-24 hr, and filtering to obtain the topical infusion. The external use infusion provided by the invention contains the tail wine, the ginger juice and the green pepper juice, the tail wine is used as a main component, the tail wine fermented by grains can be secondarily utilized, the utilization efficiency of the tail wine is improved, the organic components in the tail wine can dissolve the effective substances in the green pepper juice and the ginger juice so as to improve the leaching rate of the effective components, and the ethanol in the tail wine has the disinfection and sterilization effects and can disinfect and sterilize diseased nails.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, and particularly relates to an external use infusion for treating onychomycosis by combining traditional Chinese medicines and a preparation method thereof.
Background
Onychomycosis refers to a disease caused by dermatophyte invading the nail plate or under the nail, is a mycosis of nails of fingers (toes) of hands and feet, often occurs after tinea manus and pedis, and can also occur simultaneously, is commonly called as 'onychomycosis', and is similar to 'goose paw wind' and 'greasy onychomycosis' in the traditional Chinese medicine. The nail usually turns color, loses luster, thickens and becomes brittle, uneven, brown or grey white, and the heavy nail plate is separated from the nail bed. Onychomycosis is an infection of the nail caused by fungi such as dermatophytes, yeasts and non-dermatophytes. Onychomycosis is common: fungal onychomycosis (superficial onychomycosis), a type of lesion limited to one piece of the nail or its tip; the onychomycosis includes distal lateral type, proximal hyponychium type and superficial white type, and the lesions start from both sides or distal end of the nail, and then the hyponychium is infected.
The current treatment means include surgical nail removal, oral medicine and external therapy. The operative nail pulling is suitable for single-shot nails, and the method has large wound surface, bleeding and easy infection. The postoperative patient generally feels more pain, is easy to re-infect and relapse, and is rarely used clinically. Patients with heart disease, hypertension, diabetes, etc. are not suitable for surgical treatment. The oral administration medicine is suitable for a plurality of nails (toes), for example, 250mg of terbinafine tablets are orally taken every day for 6-12 weeks continuously; 400 mg/day of itraconazole, continuously taking for 7 days, and taking a rest for 21 days as a treatment course, wherein the treatment course lasts for 3-6 treatment courses; 150mg of fluconazole is taken 1-2 times a week for more than 4 months continuously. Can be used for treating more than 80% of onychomycosis and onychomycosis. However, because the medicines can play an antibacterial role only by reaching the deck where fungi are parasitized, the dosage is large, the administration time is long, and the adverse reaction of the medicines is monitored regularly. The external therapy mainly comprises local application, package cutting, etc., such as grinding irregular bad nails with nail file, preferably once every 2 days; then applying 30% glacial acetic acid or 10% glacial acetic acid on the affected part A for 1 time per day for more than 3-6 months. If the diseased nails are thinned before the application, the curative effect is better. Care should be taken to protect the periungual skin with mild ointment prior to nail application; or topical antifungal agents such as terbinafine tincture, amorolfine liniment, ciclopirox olamine ketone liniment, etc.
Terbinafine and itraconazole are orally taken to treat onychomycosis, although the clinical curative effect is good, in 2002, the U.S. food and drug administration gives a warning to alert the risk of serious adverse drug reactions related to itraconazole and terbinafine, which indicates that the two drugs may cause serious liver function damage, liver failure and even death, and itraconazole may also cause congestive heart failure. Meanwhile, the elderly, children and patients with liver and kidney insufficiency are not suitable for systemic medication.
Therefore, how to develop a traditional Chinese medicine preparation for treating onychomycosis becomes an urgent problem to be solved in the prior art.
Disclosure of Invention
The invention aims to provide an external Chinese medicinal composition infusion for treating onychomycosis, which contains tail wine, green zanthoxylum juice and ginger juice, can disinfect and sterilize diseased nails, has the efficacy of relieving itching and can cure onychomycosis.
The invention also aims to provide a preparation method of the external-use infusion for treating onychomycosis by combining traditional Chinese medicines, which is characterized in that the tail wine obtained by fermenting the grain grains is directly mixed with the ginger juice and the green pepper juice, the preparation method is simple, the requirements on the preparation environment and equipment are low, and the external-use infusion can be produced in large scale and can be prepared by self.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
On one hand, the embodiment of the invention provides an external use infusion for treating onychomycosis by combining traditional Chinese medicines, which comprises the following components in parts by weight: 40-50 parts of tail wine, 2-10 parts of ginger juice and 2-5 parts of green pepper juice.
On the other hand, the embodiment of the invention provides a preparation method of the externally applied traditional Chinese medicine infusion for treating onychomycosis, which comprises the steps of uniformly mixing the tail wine, the ginger juice and the green pepper juice according to a proportion, standing for 18-24 hours and filtering.
Compared with the prior art, the embodiment of the invention has at least the following advantages or beneficial effects:
the external use infusion provided by the invention contains the tail wine, the ginger juice and the green pepper juice, the tail wine is used as a main component, the tail wine fermented by grains can be secondarily utilized, the utilization efficiency of the tail wine is improved, in addition, the tail wine contains rich organic components such as acid, ester, alcohol, aldehyde, ketone and the like, compared with alcohol, the components in the tail wine are more rich, the ginger juice and the green pepper juice are added into the tail wine, the organic components in the tail wine can dissolve effective substances in the green pepper juice and the ginger juice, the leaching rate of the effective components is improved, the content of the effective components dissolved in the tail wine is high, and the effective components can better enter pores of skin to deeply disinfect the pores to treat onychomycosis; on the other hand, the ethanol in the tail wine has the function of disinfection and sterilization, and can disinfect and sterilize diseased nails.
The green pricklyash peel juice contains a large amount of limonene, and the limonene can inhibit the propagation of staphylococcus aureus, aspergillus niger and escherichia coli. The compound is matched with the tail wine to realize synergistic interaction, so that the sterilization effect is further improved.
The ginger juice mainly contains zingerone, gingerol and gingerol, and has certain volatility. The ginger juice is added into the tail wine and applied to the treatment of onychomycosis, and in the treatment process, the zingerone, the gingerol and the gingerol in the ginger juice can enhance and accelerate the blood circulation of the affected skin position, so that the skin can absorb the effective components in the ginger juice and the green pepper juice more easily, and the treatment effect of the external infusion is improved.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
On one hand, the embodiment of the invention provides an external use infusion for treating onychomycosis by combining traditional Chinese medicines, which comprises the following components in parts by weight: 40-50 parts of tail wine, 2-10 parts of ginger juice and 2-5 parts of green pepper juice.
In the invention, 40-50 parts of the tail wine is used as a main component, the tail wine contains rich organic components such as acid, ester, alcohol, aldehyde, ketone and the like, not only has excellent disinfection and sterilization effects, but also can be used as an organic solvent to dissolve the effective components in green pricklyash peel juice and ginger juice so as to improve the leaching rate of the effective components, and the effective components dissolved in the tail wine can better enter pores of skin to deeply disinfect and sterilize the pores so as to treat onychomycosis.
The main component of the green pricklyash peel juice is limonene accounting for 25.10% of the total oil, and the limonene can inhibit the propagation of staphylococcus aureus, aspergillus niger and escherichia coli. Limonene is a safe and nontoxic bacteriostatic substance, and the limonene is accumulated on the surface of a microorganism, so that the content of unsaturated fatty acid in the membrane is greatly reduced, the components of the membrane are changed or the integrity of the membrane is damaged, and the proton power can be reduced, thereby achieving the bacteriostatic action.
Also contains 21.79% of 1, 8-cineole, and the cineole can be used in combination with other medicines for treating influenza, common cold, bacillary dysentery, enteritis, various infections (including parotitis, epidemic cerebrospinal meningitis, suppurative tonsillitis, infantile head sore, erysipelas, and traumatic infection), pulmonary tuberculosis, and various dermatoses.
Also contains 11.99% of myrcene, and small amount of a-and beta-pinene, sabinene, beta-phellandrene, beta-ocimene-X, p-cymene, alpha-terpinene, perillene, linalool, 4-terpinenic acid, efletin, alpha-terpineol, trans-caryophyllene, terpineol acetate, humulene, nerol acetate, beta-piper cubene, geraniol acetate, nerolidol isomer, etc. The pericarp also contains vanilline, skimmianine, ruthenamine, 2' -hydroxy-N-isobutyl (2E,6E,8E,10E) -dodecenamide, and paprika is N-methyl-2-heptyl-4-quinolinone, dehydroentericin, nonacosane, etc.
The ginger juice mainly contains zingerone, gingerol and gingerol, and has certain volatility. Has effects in promoting blood circulation, stimulating gastric secretion, promoting digestion, and invigorating stomach. The ginger juice is added into the tail wine and applied to treating onychomycosis, and in the treatment process, the zingerone, the gingerol and the gingerol in the ginger juice can enhance and accelerate the blood circulation of the affected skin position, so that the skin can absorb the effective components in the ginger juice and the green prickleyash juice more easily, and the treatment effect of the external use infusion is improved.
In some embodiments of the present invention, the external use infusion for onychomycosis comprises the following components in parts by weight: 45 parts of tail wine, 7 parts of ginger juice and 3 parts of green pepper juice. Under the proportion, after the external use infusion is used for a long time by a patient, the treatment effect on onychomycosis is good, and meanwhile, the external use infusion has small irritation to skin and can be used for a long time.
In some embodiments of the present invention, the tail wine is one of a glutinous rice tail wine, a rice tail wine and a sorghum tail wine.
On the other hand, the embodiment of the invention provides a preparation method of the externally applied traditional Chinese medicine infusion for treating onychomycosis, which comprises the steps of uniformly mixing the tail wine, the ginger juice and the green pepper juice according to a proportion, standing for 18-24 hours and filtering. In the process of placing, the effective components in the ginger and the pepper can be fully dissolved in the tail liquor, so that the leaching rate of the effective components is improved, the content of the effective components in the tail liquor is high, and the treatment effect of the external infusion is improved.
In some embodiments of the invention, the method of preparing the tail wine comprises the steps of:
s1 soaking grains, steaming, spreading and airing;
s2 adding distiller' S yeast, sealing and fermenting;
s3 distilling, collecting the first fermented wine, fermenting the wine dregs, and distilling to collect the tail wine.
In some embodiments of the present invention, in the step S1, the cooking temperature is 90-120 ℃.
In some embodiments of the invention, in the step S2, the mass ratio of the distiller' S yeast to the grain is (0.5-1.5): 10.
In some embodiments of the present invention, in the step S2, the sealed fermentation time is 2-3 months.
In some embodiments of the invention, the ginger juice is prepared by: selecting fresh ginger, cleaning, adding the soaking solution, mixing uniformly, adding into a juicer, juicing, filtering, concentrating, and collecting juice.
In some embodiments of the present invention, the green pepper juice is prepared by the following steps: mixing fresh fructus Zanthoxyli with solvent, soaking for 3-4 days, adding into crusher, crushing, filtering, concentrating, and collecting juice.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
Preparing the tail wine
Soaking Oryza Glutinosa in cold water for 24 hr, changing water every 6 hr, steaming at 100 + -2 deg.C, and spreading for air drying. When the temperature of the sticky rice is reduced to 25 +/-1 ℃, mixing the components in a mass ratio of 1: 10 mixing with distiller's yeast. Putting the mixed distiller's yeast clinker into a barrel, covering with a layer of preservative film, then covering with a layer of plastic cloth, binding with an elastic band, standing and fermenting for 2 months. After the first fermentation wine in the collecting barrel, the wine residue is continuously fermented for 2 months, and the wine residue is collected to be the tail wine.
Preparing ginger juice
Cleaning fresh ginger, slicing, adding water, placing in a container, soaking for 2 hr, adding water and ginger in the container into a juicer, squeezing to obtain juice, filtering with filter cloth, collecting juice, and concentrating at 30 deg.C until the water content is 10 wt% to obtain ginger juice.
Preparing green pricklyash peel juice
Mixing fresh fructus Zanthoxyli with ethanol water solution, soaking for 3 days, adding fructus Zanthoxyli and solvent into a crusher, crushing, filtering, collecting juice, and concentrating at 30 deg.C until water content is 10 wt% to obtain green fructus Zanthoxyli juice.
Preparation of an infusion for external use
Weighing 450g of tail wine, 70g of ginger juice and 30g of green pepper juice, uniformly mixing, standing for 18h, stirring 1 time every 1h in the standing process, stirring for 10min every time, standing for 18h, and then filtering to obtain the external infusion.
Example 2
Preparing the tail wine
Soaking rice in cold water for 24 hr, changing water every 7 hr, steaming at 110 + -2 deg.C, and spreading for air drying. When the temperature of the rice is reduced to 25 +/-1 ℃, the weight ratio of the rice to the water is 1.5: 10 mixing with distiller's yeast. Putting the mixed distiller's yeast clinker into a barrel, covering with a layer of preservative film, then covering with a layer of plastic cloth, binding with an elastic band, standing and fermenting for 2 months. After the first fermentation wine in the collecting barrel, the wine residue is continuously fermented for 2 months, and the wine residue is collected to be the tail wine.
Preparing ginger juice
Cleaning fresh ginger, slicing, adding water, placing in a container, soaking for 1.5 hr, adding water and ginger in the container into a juicer, squeezing to obtain juice, filtering with filter cloth, collecting juice, and concentrating at 30 deg.C until the water content is 15 wt% to obtain ginger juice.
Preparing green pricklyash peel juice
Mixing fresh fructus Zanthoxyli with ethanol water solution, soaking for 4 days, adding fructus Zanthoxyli and solvent into a crusher, crushing, filtering, collecting juice, and concentrating at 30 deg.C until water content is 15 wt% to obtain green fructus Zanthoxyli juice.
Preparation of an infusion for external use
Weighing 500g of tail wine, 20g of ginger juice and 50g of green pepper juice, uniformly mixing, standing for 20h, stirring 1 time every 1h in the standing process, stirring for 10min every time, standing for 20h, and then filtering to obtain the external infusion.
Example 3
Preparing the tail wine
Soaking sorghum in cold water for 24 hr, changing water every 6 hr, steaming at 90 + -2 deg.C, and spreading for air drying. When the temperature of the sorghum is reduced to 25 +/-1 ℃, the mass ratio of the sorghum to the sorghum is 0.5: 10 mixing with distiller's yeast. Putting the mixed distiller's yeast clinker into a barrel, covering with a layer of preservative film, then covering with a layer of plastic cloth, binding with an elastic band, standing and fermenting for 3 months. After the first fermentation wine in the collecting barrel, the wine residue is continuously fermented for 3 months, and the wine is collected, namely the tail wine.
Preparing ginger juice
Cleaning fresh ginger, slicing, adding water, placing in a container, soaking for 3 hr, adding water and ginger in the container into a juicer, squeezing to obtain juice, filtering with filter cloth, collecting juice, and concentrating at 30 deg.C until the water content is 10 wt% to obtain ginger juice.
Preparing green pricklyash peel juice
Mixing fresh fructus Zanthoxyli with ethanol water solution, soaking for 3 days, adding fructus Zanthoxyli and solvent into a crusher, crushing, filtering, collecting juice, and concentrating at 30 deg.C until water content is 10 wt% to obtain green fructus Zanthoxyli juice.
Preparation of an infusion for external use
Weighing 400g of tail wine, 100g of ginger juice and 20g of green pepper juice, uniformly mixing, standing for 24h, stirring 1 time every 1h in the standing process, stirring for 10min every time, standing for 24h, and then filtering to obtain the external infusion.
Example 4
The tail wine, the ginger juice and the green pepper juice prepared in the example 1 are adopted to prepare the external infusion according to the following mixture ratio:
weighing 480g of tail wine, 50g of ginger juice and 50g of green pepper juice, uniformly mixing, standing for 24h, stirring 1 time every 1h in the standing process, stirring for 10min every time, standing for 24h, and then filtering to obtain the external infusion.
Example 5
The tail wine, the ginger juice and the green pepper juice prepared in the example 1 are adopted to prepare the external infusion according to the following mixture ratio:
weighing 500g of tail wine, 90g of ginger juice and 30g of green pepper juice, uniformly mixing, standing for 20h, stirring 1 time every 1h in the standing process, stirring for 10min every time, standing for 20h, and then filtering to obtain the external infusion.
Example 6
The tail wine prepared in example 1, the ginger juice prepared in example 2 and the green pepper juice are used to prepare an external infusion according to the following mixture ratio:
weighing 420g of tail wine, 70g of ginger juice and 40g of green pepper juice, uniformly mixing, standing for 24h, stirring 1 time every 1h in the standing process, stirring for 10min every time, standing for 24h, and then filtering to obtain the external infusion.
Examples of the experiments
1. Determination of MIC for infectious Strain
The test drugs were prepared by using the infusion solutions of examples 1 to 6, and the Minimum Inhibitory Concentrations (MIC) of the drugs against Staphylococcus aureus, Escherichia coli, Shigella dysenteriae, Candida albicans, Proteus, and Salmonella typhi were determined by tube dilution.
The liquid culture medium was added to 1.0mL of each tube with different concentrations of the drug solutions to give final concentrations of 800.00, 400.00, 200.00, 100.00, 50.00, 25.00, 12.50, 6.25, and 3.13mg/mL, respectively, and a final total volume of 1mL for each tube. Additionally, a normal control containing equal amount of MH liquid culture medium without any drug and a positive control containing bacteria and MH liquid culture medium without any drug are arranged. The concentration of each experimental tube is 2 multiplied by 107CFU/mL of fresh culture of each strain in logarithmic growth phase was 0.1mL, and the culture was incubated at 37 ℃ for 24 hours for observation. And (3) culturing the candida albicans in a culture environment at 28 ℃ for 48h to observe the result, and observing the growth conditions of different strains by naked eyes, wherein the highest dilution of the medicine without bacterial growth is MIC. The results are shown in Table 1.
TABLE 1 minimum inhibitory concentrations (mg/mL) of the topical infusions of examples 1-6
As can be seen from Table 1 above, the minimum inhibitory concentrations of the infusions for external use of examples 1 to 6 were low, wherein the minimum inhibitory concentration for Staphylococcus aureus was 6.25mg/mL, the minimum inhibitory concentration for Escherichia coli was 12.5mg/mL, the minimum inhibitory concentration for Proteus was 25mg/mL, the minimum inhibitory concentration for Salmonella typhi was 25mg/mL, the minimum inhibitory concentration for Shigella dysenteriae was 50mg/mL, and the minimum inhibitory concentration for Candida albicans was 25 mg/mL. It can be shown that the infusions for external use of examples 1 to 6 of the present invention have excellent sterilizing efficacy and good sterilizing effect even at low concentration. The external use infusion is used for treating onychomycosis, and has a sterilization effect by adopting a soaking or spraying mode.
2. Determination of intestinal infection strain bacteriostatic diameter
The test drugs were the external infusions of examples 1 to 6, and the control drugs were ampicillin, norfloxacin and fluconazole, respectively, to determine the inhibitory diameters of Staphylococcus aureus, Escherichia coli, Shigella dysenteriae, Candida albicans, Proteus and Salmonella typhi.
The agar diffusion method (tube-disc method) was used: 2mL of nutrient agar which is melted and is kept at a constant temperature of about 58 ℃ and 0.1mL of logarithmic phase bacterial liquid (the concentration of the bacterial liquid is 1 multiplied by 10) are respectively added into a sterile test tube7CFU/mL), mixing, pouring into prepared plate, spreading, condensing, adding 3 oxford cups with diameter of 6mm, transferring 200 μ L of test solution with quantitative pipettor, repeating for 2 times, making parallel holes for 3 times, and setting positive drug control. After culturing for 24h in an incubator at 37 ℃, the diameters of two vertical directions of each inhibition zone are respectively measured by a vernier caliper, and the edge of the inhibition zone is limited to the limit that bacteria can not obviously grow by naked eyes. The results are shown in Table 2.
TABLE 2 bacteriostatic diameter (mm) of each drug
Staphylococcus aureus | Escherichia coli | Proteobacteria | Salmonella typhi | Dysentery bacillus | Candida albicans | |
Example 1 | 20.72±0.14+ | 18.35±0.10+ | 16.44±0.14+ | 16.00±0.11+ | 17.37±0.14+ | 15.89±0.17+ |
Example 2 | 21.56±0.13+ | 17.89±0.11+ | 15.34±0.14+ | 16.12±0.11+ | 17.02±0.15+ | 15.78±0.16+ |
Example 3 | 20.23±0.11+ | 17.56±0.10+ | 16.12±0.16+ | 16.89±0.12+ | 16.89±0.13+ | 15.02±0.13+ |
Example 4 | 21.15±0.14+ | 18.12±0.13+ | 16.79±0.17+ | 17.02±0.11+ | 16.78±0.14+ | 15.14±0.12+ |
Example 5 | 20.89±0.14+ | 17.02±0.15+ | 17.02±0.15+ | 17.32±0.12+ | 17.02±0.12+ | 15.24±0.18+ |
Example 6 | 20.56±0.14+ | 17.78±0.14+ | 16.12±0.12+ | 16.56±0.11+ | 17.13±0.12+ | 15.69±0.17+ |
Ampicillin | 27.21±0.14 | 25.75±0.13 | 24.79±0.14 | 25.75±0.13 | 23.48±0.16 | 15.89±0.23+ |
Norfloxacin hydrochloride | 25.27±0.11 | 26.00±0.10 | 26.14±0.13 | 26.08±0.14 | 25.65±0.12 | / |
Fluconazole | / | / | / | / | / | 26.00±0.12 |
Note: compared with norfloxacin+P<0.05。
As can be seen from the above Table 2, the external infusions of examples 1 to 6 have good bacteriostatic effects on Staphylococcus aureus, Escherichia coli, Bacillus dysenteriae, Candida albicans, Bacillus proteus and Salmonella typhi, and are superior to conventional commercially available bactericidal agents. When the external preparations of examples 1 to 6 were used for treating onychomycosis, the affected part was deeply sterilized by the external preparations to inhibit the propagation of various germs, thereby treating the onychomycosis.
3. Effect on Candida albicans
The test article was diluted with M-H liquid medium (liquid medium of Sabouraud's dextrose for Candida albicans) using a 2-fold sequential broth dilution method. Taking 10 clean sterile test tubes, adding 2.0mL of M-H broth (the first tube is 2.0mL of a test sample stock solution) into each test tube except the first tube, adding 2.0mL of 1/2 (the final concentration of the test sample and the M-H broth after being uniformly mixed) into the second tube, adding 2.0mL of the third tube into the third tube, then adding 2.0mL of the third tube into the fourth tube … …, and so on to ensure that the final concentration of the experimental drugs in each tube is 1 & lt/EN & gt1. 1/2, 1/4, 1/8, 1/16, 1/32, 1/64 and 1/128 positive control (no bacteria added with the test article) and negative control (no bacteria added with the test article added with the added bacteria added with the test article added with the added bacteria added with the added. The concentration of each experimental tube is 1 multiplied by 107The growth condition of each strain of CFU/mL of the culture in the logarithmic growth phase is observed after 0.1mL of the culture in the logarithmic growth phase of each strain is cultured for 18-24h (the culture is carried out for 36-48h at 25-28 ℃ of Candida albicans) at 36 +/-1 ℃, and the highest dilution of the drug without bacterial growth is taken as the Minimum Inhibitory Concentration (MIC) of the drug. The results are shown in Table 3.
Table 3 minimum inhibitory concentrations of topical infusions of example 1
As can be seen from table 3, the external infusion of example 1 has a certain inhibitory effect on escherichia coli, staphylococcus aureus, pseudomonas aeruginosa and candida albicans, wherein the inhibitory effect on fungi (candida albicans) is superior to that of bacteria (escherichia coli, staphylococcus aureus and pseudomonas aeruginosa).
In conclusion, the Chinese medicinal preparation is prepared by mixing the glutinous rice tail wine, the sorghum tail wine, the ginger juice and the green pepper juice, and the external-use infusion has the effects of resisting bacteria and relieving itching and has better curative effect on onychomycosis. Limonene and 1, 8-cineole in the green pepper juice, and zingerone, gingerol and gingerol in the ginger juice are synergistic with the tail wine, so that blood circulation of affected skin positions is enhanced and accelerated, propagation of staphylococcus aureus, aspergillus niger and escherichia coli is inhibited, and onychomycosis can be effectively treated.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The externally-applied traditional Chinese medicine infusion for treating onychomycosis is characterized by comprising the following components in parts by weight:
40-50 parts of tail wine, 2-10 parts of ginger juice and 2-5 parts of green pepper juice.
2. The external use infusion for treating onychomycosis by combination of traditional Chinese medicines according to claim 1, which is characterized by comprising the following components in parts by weight:
45 parts of tail wine, 7 parts of ginger juice and 3 parts of green pepper juice.
3. The topical infusion of a combination of traditional Chinese medicines for treating onychomycosis according to claim 1, wherein the cocktail is one of a glutinous rice cocktail, a rice cocktail, and a sorghum cocktail.
4. A preparation method of the external use infusion for treating onychomycosis with the traditional Chinese medicine composition according to any one of claims 1 to 3, which is characterized by comprising the steps of uniformly mixing the tail wine, the ginger juice and the green pepper juice according to a proportion, standing for 18 to 24 hours and filtering.
5. The preparation method of the external use infusion for treating onychomycosis by combining traditional Chinese medicines according to claim 4, wherein the preparation method of the tail wine comprises the following steps:
s1 soaking grains, steaming, spreading and airing;
s2 adding distiller' S yeast, sealing and fermenting;
s3 distilling, collecting the first fermented wine, fermenting the wine dregs, and distilling to collect the tail wine.
6. The method for preparing the external use infusion for treating onychomycosis according to claim 5, wherein the cooking temperature in step S1 is 90-120 ℃.
7. The method for preparing the external infusion for treating onychomycosis by combining traditional Chinese medicines according to claim 5, wherein the mass ratio of the distiller' S yeast to the grains in step S2 is (0.5-1.5): 10.
8. The method for preparing the external use infusion for treating onychomycosis with combination of traditional Chinese medicines according to claim 5, wherein in the step S2, the sealed fermentation time is 2-3 months.
9. The preparation method of the external use infusion for treating onychomycosis with the traditional Chinese medicine composition according to claim 4, wherein the ginger juice is prepared by the following steps: selecting fresh ginger, cleaning, adding the soaking solution, mixing uniformly, adding into a juicer, juicing, filtering, concentrating, and collecting juice.
10. The preparation method of the external use infusion for treating onychomycosis by combining the traditional Chinese medicines according to claim 4, wherein the green zanthoxylum bungeanum juice is prepared by the following steps: mixing fresh fructus Zanthoxyli with solvent, soaking for 3-4 days, adding into crusher, crushing, filtering, concentrating, and collecting juice.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111388635.XA CN113995826A (en) | 2021-11-22 | 2021-11-22 | External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111388635.XA CN113995826A (en) | 2021-11-22 | 2021-11-22 | External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113995826A true CN113995826A (en) | 2022-02-01 |
Family
ID=79929789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111388635.XA Pending CN113995826A (en) | 2021-11-22 | 2021-11-22 | External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113995826A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108543043A (en) * | 2018-04-30 | 2018-09-18 | 石彬 | A kind of external Miao medicine for treating onychomycosis |
CN112717076A (en) * | 2021-03-17 | 2021-04-30 | 湖南翰坤实业有限公司 | Ointment for treating onychomycosis and preparation method thereof |
-
2021
- 2021-11-22 CN CN202111388635.XA patent/CN113995826A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108543043A (en) * | 2018-04-30 | 2018-09-18 | 石彬 | A kind of external Miao medicine for treating onychomycosis |
CN112717076A (en) * | 2021-03-17 | 2021-04-30 | 湖南翰坤实业有限公司 | Ointment for treating onychomycosis and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
无: "花椒有治疗灰指甲的作用吗?灰指甲可以治好吗?", 《三顶养生网》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2408372C2 (en) | Application of octenidine dihydrochloride in semisolid preparations | |
CN107812137A (en) | A kind of draft skin bacteriostatic gel of propolis-containing and preparation method thereof | |
WO2017101790A1 (en) | Pharmaceutical composition for treating cutaneous pruritus and use thereof | |
WO2010150245A1 (en) | Pharmaceutical and cosmeceutical compositions containing cannabis flower and seed extracts | |
US20200179473A1 (en) | Anti-pathogenic compositions | |
CN108042578A (en) | A kind of health care vaginal jellies containing compound probiotic ingredient | |
CN109288889A (en) | A kind of antibacterial gynecological composition, gel and preparation method thereof | |
ELABBOUBI et al. | Treatment of mycoses by essential oils: Mini Review | |
CN104922248A (en) | Antibacterial and anti-inflammatory Chinese herbal compound gel and preparation method thereof | |
US20220047494A1 (en) | Antibacterial, deodorization, easing of acne and atopy or skin calming-functional composition for y-zone cleanliness containing quercus acutissima sap and zinc ricinoleate | |
EP2611453B1 (en) | Antifungal composition | |
CN113995826A (en) | External use infusion for treating onychomycosis by traditional Chinese medicine combination and preparation method thereof | |
CN105748545B (en) | Application of Notoginseng radix converted saponin in preparing medicine for resisting fungi such as Epidermophyton floccosum, Trichophyton rubrum and Trichophyton mentagrophytes | |
CN101152546B (en) | Externally used preparations with functions of anti-inflammation, relieving itching and sterilization disinfection, and method for preparing the same | |
CN116782918A (en) | Traditional Chinese medicine antibacterial liquid and preparation method and application thereof | |
CN104288043B (en) | Method for preparing natural plant antibacterial hand-washing solution | |
CN112717076A (en) | Ointment for treating onychomycosis and preparation method thereof | |
CN104857116B (en) | Application of the Chinese medicine garden burnet in preparing antifungal medicine synergist | |
WO2012080186A1 (en) | Composition and use of a fermented olive leaf product for the treatment of nail and skin infections. | |
JP2013505978A (en) | Bread seed-based mixture | |
Carr | Therapeutic properties of New Zealand and Australian tea trees | |
CN111388529B (en) | Pharmaceutical composition for treating onychomycosis and preparation method thereof | |
RU2801872C1 (en) | Pharmaceutical agent of plant origin in the form of a spray | |
CN107929372A (en) | Treat Chinese medicine composition of onychomycosis and its preparation method and application | |
CN106902211A (en) | One kind scalds medicament and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220201 |